Vertex Pharmaceuticals
Boston
Massachusetts
United States
774 articles with Vertex Pharmaceuticals
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for Patients With Cystic Fibrosis Between the Ages of 4 Months and 18 Years With the R117H Mutation in the CFTR Gene
3/25/2022
Vertex Pharmaceuticals (Canada) Incorporated (NASDAQ: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrKALYDECO® (ivacaftor) in patients from 4 months to 18 years of age and weighing at least 5 kg with the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
-
Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8
3/1/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:50 p.m. ET.
-
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
-
Despite the massive financing from venture capitalists that poured into Massachusetts in 2021, Bay State biopharma companies are struggling to find enough talent to fill the number of available jobs.
-
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
1/26/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2021 and provided full year 2022 financial guidance.
-
SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmaceuticals to Advance NaV1.7 Inhibitors for the Treatment of Pain
1/19/2022
SiteOne will be responsible for research and early preclinical development activities; Vertex will be responsible for development, and commercialization.
-
Precision Gene Therapy on the Cusp
1/11/2022
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences. -
Sangamo Therapeutics announced that Sanofi US was returning its rights to SAR445136 as it shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.
-
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
1/4/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET.
-
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
-
Here’s a look at 10 of the more compelling research stories of the year.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.
-
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
-
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
11/19/2021
Vertex Pharmaceuticals Incorporated announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
11/12/2021
Vertex Receives CHMP Positive Opinion for KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
-
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
-
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.